pharmacie et médicaments – Interdiction du Qalsody pour les personnes atteintes de SLA

This written question concerns the drug Qalsody and its potential ban for individuals suffering from Amyotrophic Lateral Sclerosis (ALS). It seeks clarification on the regulatory status and reasons behind any proposed restrictions. The question impacts patients with ALS, their families, and healthcare providers. It raises concerns about access to potentially life-altering treatments and the decision-making process for drug approvals or bans.